In right on the money…, I was talking about a "numb" feeling after watching Neal Parker speak for AbbVie last week [a deal-breaker?…]. I remembered another time I felt it. It was in January 2012 and I was at the trial in Austin Texas of Allen Jones and the State of Texas versus Janssen [AKA […]
Back in the late 1970s when the cry for evidence based proof was in its youth and psychiatry was changing, there was a lot of talk about this topic. Cognitive Behavior Therapy was kind of new, and all the rage. Beck was a clear thinker and he won us all over first with "depressive thinking" […]
Like many others, a few days ago I wrote a deal-breaker?…, a post about AbbVie’s lawyer, Neal Parker, who appeared at the Brussels Conference, A Roadmap for Sharing Clinical Data. Among other things, he said: … internal tactical decisions on how we are going to run a study, engage with regulators, and confront and solve […]
UK trial rules tightened up Pharmafile by Adam Hill Published on 11/09/13 at 02:03pm Anyone wanting to conduct clinical trials in the UK will have to register their research in order to receive a ‘favourable ethical opinion’ before they can begin, according to new rules to be introduced at the end of the month. The […]
Who would’ve thought that I would end up reading stuff about the Clinical Trial industry? Not me. I guess I could take solace in some old saying like "variety is the spice of life," but whatever path got me here, here I go again. In a Randomized, Double Blind Clinical Trial, the way things are […]
Non-Profit Leaves Collaboration With Industry Over Glaxo Stance Pharmalot by Ed Silverman 09/09/2013 Five years after the Innovative Medicines Initiative was launched with big hopes of regenerating drug development and discovery in Europe [back story], a high-profile clash has broken out among some of the participants – one of the world’s largest drugmakers and a […]
Physicians Under the Influence: Social Psychology and Industry Marketing Strategies by Sunita Sah and Adriane Fugh-Berman Journal of Law, Medicine and Ethics. 2013 14[3]:– Pharmaceutical and medical device companies apply social psychology to influence physicians’ prescribing behavior and decision-making. Physicians fail to recognize their vulnerability to commercial influences; due to self-serving bias, rationalization, and cognitive […]
“Hardly worth the effort”? Medical journals’ policies and their editors’ and publishers’ views on trial registration and publication bias: quantitative and qualitative study by Elizabeth Wager and Peter Williams British Medical Journal. 2013 347:f5248 published on-line September 6, 2013 [full text on-line] Objectives To determine the proportion of medical journals requiring trial registration and to […]
In that video [a deal-breaker?…], Neal Parker of AbbVie, tells us that there are secrets in the Pharmaceutical Companies negotiations with regulators that might help the evil-doers in Bangladesh do a bio-equivalency study, clone his company’s product, and steal their business right out from under them. It might even be important to keep Adverse Effects […]
Who was that guy? The one in the video that seemed so outrageous [a deal-breaker?…, a window…]. And where was that meeting? What was it about? Neal Parker Section Head Legal – Biologics Strategic Development, Abbvie Neal Parker is a U.S. lawyer specializing in drug and biologic regulatory issues. He began his career more than […]